Výsledky vyhledávání - "recombinant factor VIII Fc"

Akademický článek

CLINICAL EFFICACY OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN IN HAEMOPHILIA A PATIENT RECEIVING ON DEMAND TREATMENT ONLY

Autor: Saima Zahir, Tahira Zafar, Altaf Hussain, Hamid Saeed Malik, Pervez Ahmed, Saleem Ahmed Khan

Publikováno v: Pakistan Armed Forces Medical Journal, Vol 71, Iss 1, Pp 62-66 (2021)

Objective: To evaluate the efficacy of recombinant factor VIII FC fusion protein in haemophilia A patient receiving on demand treatment only. Study Design: Comparative cross sectional study. Place and Duration of Study: Department of Hematology

Externí odkaz: https://doaj.org/article/c23e28d5cefa4fad8017bd77710391d3

Zobrazit plný text záznamu

Akademický článek

Effect of tertiary prophylaxis with low-dose factor VIII in quality of life in adult patients with severe hemophilia A

Autor: Prakas Kumar Mandal, Abhijit Phukan, Amrita Bhowmik, Debasis Gantait, Prantar Chakrabarti

Publikováno v: Journal of Applied Hematology, Vol 10, Iss 3, Pp 88-93 (2019)

BACKGROUND: Hemophilia A, characterized by deficiency of factor VIII (FVIII), is an X-linked bleeding disorder. It is graded as mild, moderate, or severe based on the FVIII level in plasma. Bleeding-related complications are often associated with sev

Externí odkaz: https://doaj.org/article/8bf613e87e304c2ca6f026370ccd2879

Zobrazit plný text záznamu

Akademický článek

Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the FcγRIIB Receptor

Autor: Maria T. Georgescu, Paul C. Moorehead, Tongyao Liu, Jennifer Dumont, David W. Scott, Christine Hough, David Lillicrap

Publikováno v: Frontiers in Immunology, Vol 11 (2020)

The development of neutralizing antibodies (inhibitors) against factor VIII (FVIII) is a major complication of hemophilia A treatment. The sole clinical therapy to restore FVIII tolerance in patients with inhibitors remains immune tolerance induction

Externí odkaz: https://doaj.org/article/a2ee070406e647a2aa15fff3c1819720

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Real‐world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A follow‐up retrospective analysis

Autor: Victoria Price, Haowei Linda Sun, Nisha Jain, Elisa Tsao, Jennifer A. Dumont, Janice M. Staber, Hilda Ding, Manuel Carcao, Zahra Al-Khateeb, Mark Belletrutti, Sanjay P Ahuja, MacGregor Steele, Steven W. Pipe, Amy D. Shapiro, Michael Wang, Jing Feng, Nina Hwang, Kenneth Lieuw

Publikováno v: Haemophilia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37f9db0f7331eaa32d88d74bebbbc66e
http://europepmc.org/articles/PMC8243250

Zobrazit plný text záznamu

A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients

Publikováno v: Thrombosis and Haemostasis, 120(5), 747-757. Georg Thieme Verlag
Thrombosis and haemostasis, 120(5), 747-757. Schattauer GmbH
Thrombosis and Haemostasis, 120(5), 747-757. GEORG THIEME VERLAG KG

Background The currently published population pharmacokinetic (PK) models used for PK-guided dosing in hemophilia patients are based on clinical trial data and usually not externally validated in clinical practice. The aim of this study was to valida

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2725ef1b451329b318ac247f4e9fa808
https://pure.eur.nl/en/publications/ab0d2602-2004-4fbd-a4b7-d10d7bf577ca

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype

Autor: Frank Driessler, Robert T. Peters, Maricel G. Miguelino, Glenn F. Pierce, Jurg M. Sommer

Publikováno v: Blood Coagulation & Fibrinolysis

The aim of this study was to compare the hemostatic efficacy of recombinant factor VIII Fc (rFVIIIFc) (Eloctate) and Advate by ex-vivo rotation thromboelastometry (ROTEM) of whole blood and to explore potential ROTEM parameters that may be more predi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d96c24c34193841701fc61de250a48b
https://doi.org/10.1097/mbc.0000000000000638

Zobrazit plný text záznamu

Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: The A-SURE study

Autor: Johan Szamosi, Flora Peyvandi, Charles R. M. Hay, Jean François Schved, Bent Winding, Johannes Oldenburg, Stefan Lethagen, Víctor Jiménez-Yuste

Publikováno v: Biblos-e Archivo. Repositorio Institucional de la UAM
instname
BMJ Open

Introduction: Haemophilia A is a rare bleeding disorder caused by coagulation factor VIII (FVIII) deficiency. This is treated with factor VIII, conventionally using products with a half-life of 8-12 hours typically administered every 2-3 days. Recomb

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bcc839e026b03d26be855f9ab1e3efc
http://hdl.handle.net/10486/689036

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání